Abstract
We tested the hypothesis that stimulation of adiponectin receptors with the synthetic agonist AdipoRon suppresses proliferation and induces apoptotic death in human high grade serous ovarian tumor cell lines and in ex vivo primary tumors, mediated by activation of 5′ AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin (mTOR). We determined the effect of AdipoRon on high grade serous ovarian tumor cells lines (OVCAR3, OVCAR4, A2780) and ex vivo primary tumor tissue. Western blotting analysis was performed to examine changes in activation of AMPK and mTOR signaling and flow cytometry was utilized to examine changes in cell cycle progression. Immunofluorescence of cleaved caspase-3 positive cells and flow cytometry of annexin V positive cells were used to determine changes in apoptotic response. The CyQUANT proliferation assay was used to assess cell proliferation. AdipoRon treatment increased AMPK phosphorylation (OVCAR3 P = 0.01; A2780 P = 0.02) but did not significantly alter mTOR activity. AdipoRon induced G1 cell cycle arrest in OVCAR3 (+ 12.1%, P = 0.03) and A2780 (+ 12.0%, P = 0.002) cells. OVCAR3 and OVCAR4 cells treated with AdipoRon underwent apoptosis based on cleaved caspase-3 and annexin V staining. AdipoRon treatment resulted in a dose dependent decrease in cell number versus vehicle treatment in OVCAR3 (−61.2%, P < 0.001), OVCAR4 (−79%, P < 0.001), and A2780 (−56.9%, P < 0.001). Ex vivo culture of primary tumors treated with AdipoRon resulted in an increase in apoptosis measured with cleaved caspase-3 immunohistochemistry. AdipoRon induces activation of AMPK and exhibits an anti-tumor effect in ovarian cancer cell lines and primary tumor via a mTOR-independent pathway.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA 68:7–30. https://doi.org/10.3322/caac.21442
National Cancer Institute Cancer Stat Facts: ovarian cancer
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, Gonzalez-Martin A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA, Investigators E-ON (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154–2164. https://doi.org/10.1056/NEJMoa1611310
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83
Combs TP, Marliss EB (2014) Adiponectin signaling in the liver. Rev Endocr Metab Disord 15:137–147. https://doi.org/10.1007/s11154-013-9280-6
Moon HS, Chamberland JP, Aronis K, Tseleni-Balafouta S, Mantzoros CS (2011) Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans. Mol Cancer Ther 10:2234–2243. https://doi.org/10.1158/1535-7163.MCT-11-0545
Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, Kim SE, Lee GY, Lee JW, Jung SA, Chung HY, Jeong S, Kim JB (2010) Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 24:1441–1452. https://doi.org/10.1210/me.2009-0498
Li G, Cong L, Gasser J, Zhao J, Chen K, Li F (2011) Mechanisms underlying the anti-proliferative actions of adiponectin in human breast cancer cells, MCF7-dependency on the cAMP/protein kinase-A pathway. Nutr Cancer 63:80–88. https://doi.org/10.1080/01635581.2010.516472
Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM (2007) Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 43:690–709. https://doi.org/10.1016/j.ejca.2006.11.010
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638. https://doi.org/10.1056/NEJMoa021423
Jin JH, Kim HJ, Kim CY, Kim YH, Ju W, Kim SC (2016) Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer. Obstet Gynecol Sci 59:279–285. https://doi.org/10.5468/ogs.2016.59.4.279
Otokozawa S, Tanaka R, Akasaka H, Ito E, Asakura S, Ohnishi H, Saito S, Miura T, Saito T, Mori M (2015) Associations of serum isoflavone, adiponectin and insulin levels with risk for epithelial ovarian cancer: results of a case-control study. Asian Pac J Cancer Prev 16:4987–4991
Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T (2013) A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503:493–499. https://doi.org/10.1038/nature12656
Li X, Yu Z, Fang L, Liu F, Jiang K (2017) Expression of adiponectin receptor-1 and prognosis of epithelial ovarian cancer patients. Med Sci Monit 23:1514–1521
Tiwari A, Ocon-Grove OM, Hadley JA, Giles JR, Johnson PA, Ramachandran R (2015) Expression of adiponectin and its receptors is altered in epithelial ovarian tumors and ascites-derived ovarian cancer cell lines. Int J Gynecol Cancer 25:399–406. https://doi.org/10.1097/igc.0000000000000369
Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP (2012) DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol 127:241–248. https://doi.org/10.1016/j.ygyno.2012.06.017
Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66:188–193
McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT et al (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46:4244s–4248s
Li W, Saud SM, Young MR, Chen G, Hua B (2015) Targeting AMPK for cancer prevention and treatment. Oncotarget 6:7365–7378. https://doi.org/10.18632/oncotarget.3629
Kwon HK, Bae GU, Yoon JW, Kim YK, Lee HY, Lee HW, Han JW (2002) Constitutive activation of p70S6 k in cancer cells. Arch Pharm Res 25:685–690
Hoffmann M, Gogola J, Ptak A (2018) Adiponectin reverses the proliferative effects of estradiol and IGF-1 in human epithelial ovarian cancer cells by downregulating the expression of their receptors. Horm Cancer 9:166–174. https://doi.org/10.1007/s12672-018-0331-z
National Cancer Institute The Cancer Genome Atlas
Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4:2126. https://doi.org/10.1038/ncomms3126
Yung MM, Ngan HY, Chan DW (2016) Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges. Acta Biochim Biophys Sin 48:301–317. https://doi.org/10.1093/abbs/gmv128
Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D (2009) LKB1 is required for adiponectin-mediated modulation of AMPK-S6 K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28:2621–2633. https://doi.org/10.1038/onc.2009.129
Cheaib B, Auguste A, Leary A (2015) The PI3 K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer 34:4–16. https://doi.org/10.5732/cjc.014.10289
Xu J, Ji J, Yan XH (2012) Cross-talk between AMPK and mTOR in regulating energy balance. Crit Rev Food Sci Nutr 52:373–381. https://doi.org/10.1080/10408398.2010.500245
Liu Y, Shi L, Liu Y, Li P, Jiang G, Gao X, Zhang Y, Jiang C, Zhu W, Han H, Ju F (2018) Activation of PPARgamma mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme. Biomed Pharmacother 100:358–366. https://doi.org/10.1016/j.biopha.2018.02.006
Zhuang Y, Miskimins WK (2008) Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3:18. https://doi.org/10.1186/1750-2187-3-18
Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295. https://doi.org/10.1038/nm788
Wu Y, Song P, Zhang W, Liu J, Dai X, Liu Z, Lu Q, Ouyang C, Xie Z, Zhao Z, Zhuo X, Viollet B, Foretz M, Wu J, Yuan Z, Zou MH (2015) Activation of AMPKalpha2 in adipocytes is essential for nicotine-induced insulin resistance in vivo. Nat Med 21:373–382. https://doi.org/10.1038/nm.3826
Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K, Kobayashi M, Iwane A, Sasako T, Okazaki Y, Ohsugi M, Takamoto I, Yamashita S, Asahara H, Akira S, Kasuga M, Kadowaki T (2011) Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 13:401–412. https://doi.org/10.1016/j.cmet.2011.02.010
Habeeb BS, Kitayama J, Nagawa H (2011) Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. Cancer Sci 102:999–1006. https://doi.org/10.1111/j.1349-7006.2011.01902.x
Liu J, Lam JB, Chow KH, Xu A, Lam KS, Moon RT, Wang Y (2008) Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis 29:2195–2202. https://doi.org/10.1093/carcin/bgn194
Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ, Xu A (2006) Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66:11462–11470. https://doi.org/10.1158/0008-5472.Can-06-1969
Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662–5667. https://doi.org/10.1210/jc.2002-020635
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17:1498–1503. https://doi.org/10.1038/nm.2492
Messaggio F, Mendonsa AM, Castellanos J, Nagathihalli NS, Gorden L, Merchant NB, VanSaun MN (2017) Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth. Oncotarget 8:85378–85391. https://doi.org/10.18632/oncotarget.19905
Acknowledgements
This research was supported in part by University of Colorado Department of Obstetrics and Gynecology Academic Enrichment Fund grant. The authors appreciate the contribution to this research made by E. Erin Smith, HTL(ASCP)CM QIHC, Allison Quador, HTL(ASCP)CM, and Jessica Arnold, HTL(ASCP)CM of the University of Colorado Denver Tissue Biobanking and Histology Shared Resource. This resource is supported in part by the Cancer Center Support Grant (P30CA046934). Flow cytometry was performed by the University of Colorado Cancer Center Flow Cytometry Shared Resource (supported by NCI Cancer Center Support Grant P30CA046934). We would also like to acknowledge that imaging was made possible by the University of Colorado Advanced Light Microscopy Core, supported in part by NIH/NCRR CCTSI grant UL1 RR025780. Contents are the authors’ sole responsibility.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflicts of interest related to this work.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ramzan, A.A., Bitler, B.G., Hicks, D. et al. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem 461, 37–46 (2019). https://doi.org/10.1007/s11010-019-03586-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-019-03586-9